UK Interest in Retatrutide: What the 2026 Search Data Show
UK Interest in Retatrutide: What the 2026 Search Data Show
By the Corex Vitality™ Research Team · Last checked 3 November 2026 · Sources listed at the end
Quick summary
Retatrutide is an investigational research compound: one peptide designed to act at three receptors (GIP, GLP-1 and glucagon). It is still in clinical development and is not authorised as a medicine in the UK.
UK Google searches for it were close to zero before 2024. They reached their busiest weeks in August 2026, and stayed at about double last November’s level through October.
Short spikes in search interest showed up on 13–15 October and 28–29 October 2026.
Interest also brings risk. On 14 October the MHRA seized more than 12,000 fake retatrutide and tirzepatide pens. That is why an open, checkable COA matters more than ever.
Retatrutide has become one of the most talked-about research peptides in the UK this year. This article sets out what the public data show: search interest, the number of UK sellers, and the regulator’s response. It also explains why batch verification matters when so many products are on offer. Every figure is linked to its source. This is market and search data only. It says nothing about any effect of the compound.
1. What is retatrutide?
Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly and Company. It was designed as a single molecule that switches on three related cell-surface receptors, a so-called triple agonist. An agonist is a molecule that binds a receptor and activates it. The three receptors are:
GIPR, the receptor for the gut hormone GIP
GLP-1R, the receptor for glucagon-like peptide-1
GCGR, the receptor for glucagon
The discovery paper by Coskun and colleagues (2022) describes this receptor profile from cell assays. Our explainer on GLP-1, GIP and glucagon receptor peptides covers how these receptors signal inside the cell.
Retatrutide is still being studied by its developer. On 3 November 2026, ClinicalTrials.gov listed 14 phase 3 studies sponsored by Eli Lilly and Company. Five were marked completed, eight active and not recruiting, and one recruiting. It has not been authorised as a medicine in the UK (MHRA, 15 October 2026).
2. What the UK search data show
Weekly UK Google search interest in “retatrutide”. 100 marks the busiest week in the 12 months shown. Data: Google Trends, pulled 3 November 2026. Chart: Corex Vitality™ Science & Learning.
Google Trends does not show how many searches were made. It gives a score from 0 to 100, where 100 is the busiest point in the chosen period. We pulled UK data for the search term “retatrutide” on 3 November 2026:
Five-year view: the weekly score never rose above 1 before 2024, and peaked at 4 during 2024. It reached 42 in 2025 and 100 in August 2026 (Google Trends, 5 years).
Past 12 months: the busiest weeks were those starting 9 August and 30 August 2026 (score 100). October 2026 weeks scored between 47 and 65. That is lower than August, but still about double the 25 to 31 seen in November 2025 (Google Trends, 12 months).
October spikes: the daily score rose from 21 on 9–10 October to 40, 41 and 47 on 13–15 October. It rose again from 26 on 26–27 October to 44 and 41 on 28–29 October (Google Trends, 90 days).
Those two October windows match Google’s own trending-search lists. The tracking site Trendomap records retatrutide as a UK trending search from 13 to 14 October (“5K+” searches, +300%) and from 28 to 29 October (“2K+” searches, +700%).
A separate estimate gives a sense of scale. In a Wellbeing News report of 2 September 2026, online pharmacy Curely estimated about 155,000 UK searches for “retatrutide” in the most recent month, a 658% rise in a year. Note that this figure covers the month before early September, so it falls in the August peak.
The data show when interest rose, not why. We have not tried to link any spike to a single news story.
3. How many UK sellers list it?
Supply has grown alongside interest. In its October 2026 snapshot, the comparison site ViralPeps counted 138 retatrutide listings from 55 UK vendors. That made it the most-listed compound in the group it tracks.
More sellers mean more choice for laboratories, but also more variation in quality and in how much evidence each seller shows.
4. The other side: the MHRA’s October seizure
The MHRA (Medicines and Healthcare products Regulatory Agency) is the UK body that regulates medicines. On 14 October 2026, MHRA officers and West Midlands Police raided an industrial site in Birmingham. They seized more than 12,000 fake retatrutide and tirzepatide pens, plus packaging for around 30,000 more, valued at about £2 million (MHRA press release, 15 October 2026).
The same release lists earlier operations in October 2025, February 2026 and May 2026. It states that retatrutide has not been authorised for use in the UK.
Freedom of Information figures reported by GB News on 30 October 2026 show MHRA records involving suspected illegal retatrutide rising from 9 in 2024 to 257 in 2025. The MHRA cautioned that these records are not a definitive count of counterfeit products.
The regulator has also been clear about labels. Speaking to the BBC, the MHRA said it decides whether a product is a medicine case by case. It added that it disregards “research purposes” claims when they are used to avoid medicines rules. Our guide Are research peptides legal in the UK? explains where research supply sits.
Corex Vitality™ supplies retatrutide strictly as a research chemical for in-vitro laboratory work. We give no instructions for use in people or animals, and we make no claims about effects in the body.
5. Why verified COAs and batch transparency matter
A counterfeit pen and a mislabelled research vial share the same problem: you cannot see what is inside. For a laboratory, an unknown or impure compound can ruin an experiment, because the results cannot be traced back to a known material. A Certificate of Analysis (COA) is the lab report for one batch. Before you rely on any retatrutide sample, check:
Same compound, same size. The COA should name retatrutide and the exact size you are buying.
A traceable report. Look for a report number and the testing laboratory’s name, and use any QR or online check the laboratory offers.
Batch match. The batch or lot on the vial or pack should link to the COA you are shown.
Purity is not content. HPLC purity (how much of the material is the target peptide) is different from net peptide content. See HPLC purity vs net peptide content.
Claims that match the report. A seller should only claim the tests the COA actually shows.
Our published retatrutide COAs are from Lingda Laboratory and cover the 10mg, 20mg, 30mg, 40mg and 60mg sizes. They report HPLC purity from >99.73% to >99.76%, as well as quantity, heavy metals, endotoxin and sterility. They do not include a separate molecular-mass identity test. You can open each one on our verification page, and our step-by-step guide shows how to verify a peptide COA. Research you can verify.
Key takeaways
UK search interest in retatrutide grew from almost nothing before 2024 to its busiest weeks in August 2026, with fresh spikes in mid and late October.
Google Trends scores are relative, so read them as direction, not volume.
Seller numbers have grown too: 55 UK vendors and 138 listings in October 2026.
The MHRA is actively seizing fake pens, and retatrutide is not authorised as a medicine in the UK.
The peer-reviewed papers below were used for the science in this article. Each entry was checked against PubMed on 3 November 2026. Summaries describe laboratory, cell-assay and structural findings only. Corex Vitality™ is not affiliated with the cited authors, journals or institutions.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist […]: From discovery to clinical proof of concept. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al.. Cell Metab. 2022;34(9):1234-1247.e9. PMID: 35985340 · DOI: 10.1016/j.cmet.2022.07.013 Discovery paper describing the design of LY3437943 (retatrutide) and its in-vitro activity profile at the glucagon, GIP and GLP-1 receptors in cell-based assays.
Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. Yuliantie E, Darbalaei S, Dai A, Zhao P, Yang D, Sexton PM, et al.. Biochem Pharmacol. 2020;177:114001. PMID: 32360365 · DOI: 10.1016/j.bcp.2020.114001 HEK293 cell study comparing cAMP, ERK1/2 phosphorylation and β-arrestin2 recruitment for single-, dual- and triple-receptor peptide agonists at the GIP and GLP-1 receptors.
Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide. Chang R, Zhang X, Qiao A, Dai A, Belousoff MJ, Tan Q, et al.. J Biol Chem. 2020;295(28):9313-9325. PMID: 32371397 · DOI: 10.1074/jbc.RA120.013793 Cryo-electron microscopy structure showing how a dual-agonist peptide binds the glucagon receptor, giving structural background for multi-receptor peptides.
All Corex Vitality™ products are supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use. No information here describes use in humans or animals.
Research you can verify.
Corex Vitality™ Research Updates
Get new Learning Hub articles and stock updates. No spam. Unsubscribe any time.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Research-grade peptides supplied exclusively for in-vitro laboratory research, supported by third-party HPLC testing and transparent batch documentation. Not for human or veterinary use.
By entering this website, you confirm that you are 18 years of age or older, are visiting exclusively for in-vitro laboratory research, and agree to our Terms & Conditions and Privacy Policy.
